tiprankstipranks
Acorda Therapeutics trading halted, volatility trading pause
PremiumThe FlyAcorda Therapeutics trading halted, volatility trading pause
17d ago
Acorda Therapeutics’ Strategic Bankruptcy and Asset Sale Plan
PremiumCompany Announcements
Acorda Therapeutics’ Strategic Bankruptcy and Asset Sale Plan
18d ago
Acorda Therapeutics, Merz sign “stalking horse” asset purchase deal for $185M
PremiumThe Fly
Acorda Therapeutics, Merz sign “stalking horse” asset purchase deal for $185M
18d ago
Acorda lowers 2023 Inbrija U.S. sales outlook to $34M-$38M from $38M-$42M
PremiumThe FlyAcorda lowers 2023 Inbrija U.S. sales outlook to $34M-$38M from $38M-$42M
9M ago
Acorda Therapeutics reports Q2 EPS ($7.55) vs. ($54.01) last year
PremiumThe Fly
Acorda Therapeutics reports Q2 EPS ($7.55) vs. ($54.01) last year
9M ago
Acorda Therapeutics regains compliance with Nasdaq
PremiumThe Fly
Acorda Therapeutics regains compliance with Nasdaq
10M ago
Acorda Therapeutics Sees FY23 Ampyra Sales $74.6M – $82.4M
PremiumThe FlyAcorda Therapeutics Sees FY23 Ampyra Sales $74.6M – $82.4M
1y ago
Acorda Therapeutics sees FY23 revenue $122.2M – $135M
PremiumThe Fly
Acorda Therapeutics sees FY23 revenue $122.2M – $135M
1y ago
Acorda Therapeutics receives non-compliance letter from NASDAQ
PremiumThe Fly
Acorda Therapeutics receives non-compliance letter from NASDAQ
1y ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100